David C. W. Lau
Research Subjects
David C. W. Lau has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Hwee Teoh
Division of Cardiac Surgery (C.J.D., A.Z.H., A.K., A.Q., H.T., S.V.), St. Michael’s Hospital of Unity Health Toronto, Toronto, Ontario, Canada
3 shared publications Arya M. Sharma
Pour les membres du Groupe d'experts d'Obésité Canada sur les lignes directrices Lignes directrices canadiennes de 2006 sur la prise en charge et la prévention de l'obésité chez Ehud Ur
2 shared publicationsEhud Ur
2 shared publicationsHongyun Yan
2 shared publicationsIrene M. Hramiak
2 shared publicationsJames D. Douketis
2 shared publications
Latest Publications
- Open Access
- 28 February 2025
- Published by Elsevier in Obesity Pillars
- Vol. 14, 100171
Management and impact of obesity in Canada: A real-world survey of people with obesity and their physicians
- 28 February 2025
- Published by Elsevier in Obesity Pillars
- Vol. 14, 100171
Open AccessManagement and impact of obesity in Canada: A real-world survey of people with obesity and their physicians
- Open Access
- 3 September 2024
- Published by Wiley in Clinical Obesity
- Vol. 15 (1) , e12701
Therapeutic inertia in obesity management among people living with obesity from the perspective of general/family practitioners in Canada: A mixed‐methods study
Summary: This mixed‐methods study aimed to explore factors contributing to therapeutic inertia among people living with obesity in Canada from the perspective of general/family practitioners (GP/FPs). One‐on‐one interviews and online surveys guided by the Theoretical Domains Framework were conducted. A total of 20 general/family practitioners were interviewed and 200 general/family practitioners were surveyed. Key findings from interviews were used to guide the development of the survey. Spearman's correlation analysis evaluated the association between general/family practitioners theme domain scores and their familiarity with the 2020 Canadian Adult Obesity Clinical Practice Guidelines. The 200 general/family practitioners surveyed provided representation across Canada, with diversity in age, background, and gender. The most prominent domains related to therapeutic inertia that were positively influenced by familiarity with Clinical Practice Guidelines were Beliefs about Capabilities (rs = .27; p < .01), Skills (rs = .23; p < .01), Behavioural Regulation (rs = .24; p < .01) and Emotions (rs = .23; p < .01). Irrespective of their familiarity with Clinical Practice Guidelines, most general/family practitioners reported that environmental and contextual barriers impact obesity management. Particularly, while financial barriers were reported by participants regardless of Clinical Practice Guidelines familiarity, general/family practitioners familiar with Clinical Practice Guidelines more often reported having time to discuss obesity management with patients. This study identified perceptions, resource and training considerations that contribute to healthcare decision‐making and therapeutic inertia in obesity management among general/family practitioners and highlighted key areas to target with interventions in primary care to facilitate obesity management, which should be multi‐faceted, with a focus on incorporating obesity education into healthcare providers training programs and improving systemic and financial support.
- 3 September 2024
- Published by Wiley in Clinical Obesity
- Vol. 15 (1) , e12701
Open AccessTherapeutic inertia in obesity management among people living with obesity from the perspective of general/family practitioners in Canada: A mixed‐methods study
Summary: This mixed‐methods study aimed to explore factors contributing to therapeutic inertia among people living with obesity in Canada from the perspective of general/family practitioners (GP/FPs). One‐on‐one interviews and online surveys guided by the Theoretical Domains Framework were conducted. A total of 20 general/family practitioners were interviewed and 200 general/family practitioners were surveyed. Key findings from interviews were used to guide the development of the survey. Spearman's correlation analysis evaluated the association between general/family practitioners theme domain scores and their familiarity with the 2020 Canadian Adult Obesity Clinical Practice Guidelines. The 200 general/family practitioners surveyed provided representation across Canada, with diversity in age, background, and gender. The most prominent domains related to therapeutic inertia that were positively influenced by familiarity with Clinical Practice Guidelines were Beliefs about Capabilities (rs = .27; p < .01), Skills (rs = .23; p < .01), Behavioural Regulation (rs = .24; p < .01) and Emotions (rs = .23; p < .01). Irrespective of their familiarity with Clinical Practice Guidelines, most general/family practitioners reported that environmental and contextual barriers impact obesity management. Particularly, while financial barriers were reported by participants regardless of Clinical Practice Guidelines familiarity, general/family practitioners familiar with Clinical Practice Guidelines more often reported having time to discuss obesity management with patients. This study identified perceptions, resource and training considerations that contribute to healthcare decision‐making and therapeutic inertia in obesity management among general/family practitioners and highlighted key areas to target with interventions in primary care to facilitate obesity management, which should be multi‐faceted, with a focus on incorporating obesity education into healthcare providers training programs and improving systemic and financial support.
- Open Access
- 31 January 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 48 (5) , 683-693
Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective
Objectives: This study aimed to assess the cost-effectiveness of weight-management pharmacotherapies approved by Canada Health, i.e., orlistat, naltrexone 32 mg/bupropion 360 mg (NB-32), liraglutide 3.0 mg and semaglutide 2.4 mg as compared to the current standard of care (SoC). Methods: Analyses were conducted using a cohort with a mean starting age 50 years, body mass index (BMI) 37.5 kg/m2, and 27.6% having type 2 diabetes. Using treatment-specific changes in surrogate endpoints from the STEP trials (BMI, glycemic, blood pressure, lipids), besides a network meta-analysis, the occurrence of weight-related complications, costs, and quality-adjusted life-years (QALYs) were projected over lifetime. Results: From a societal perspective, at a willingness-to-pay (WTP) threshold of CAD 50 000 per QALY, semaglutide 2.4 mg was the most cost-effective treatment, at an incremental cost-utility ratio (ICUR) of CAD 31 243 and CAD 29 014 per QALY gained versus the next best alternative, i.e., orlistat, and SoC, respectively. Semaglutide 2.4 mg extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg and remained cost-effective both under a public and private payer perspective. Results were robust to sensitivity analyses varying post-treatment catch-up rates, longer treatment durations and using real-world cohort characteristics. Semaglutide 2.4 mg was the preferred intervention, with a likelihood of 70% at a WTP threshold of CAD 50 000 per QALY gained. However, when the modeled benefits of weight-loss on cancer, mortality, cardiovascular disease (CVD) or osteoarthritis surgeries were removed simultaneously, orlistat emerged as the best value for money compared with SoC, with an ICUR of CAD 35 723 per QALY gained. Conclusion: Semaglutide 2.4 mg was the most cost-effective treatment alternative compared with D&E or orlistat alone, and extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg. Results were sensitive to the inclusion of the combined benefits of mortality, cancer, CVD, and knee osteoarthritis.
- 31 January 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 48 (5) , 683-693
Open AccessCost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective
Objectives: This study aimed to assess the cost-effectiveness of weight-management pharmacotherapies approved by Canada Health, i.e., orlistat, naltrexone 32 mg/bupropion 360 mg (NB-32), liraglutide 3.0 mg and semaglutide 2.4 mg as compared to the current standard of care (SoC). Methods: Analyses were conducted using a cohort with a mean starting age 50 years, body mass index (BMI) 37.5 kg/m2, and 27.6% having type 2 diabetes. Using treatment-specific changes in surrogate endpoints from the STEP trials (BMI, glycemic, blood pressure, lipids), besides a network meta-analysis, the occurrence of weight-related complications, costs, and quality-adjusted life-years (QALYs) were projected over lifetime. Results: From a societal perspective, at a willingness-to-pay (WTP) threshold of CAD 50 000 per QALY, semaglutide 2.4 mg was the most cost-effective treatment, at an incremental cost-utility ratio (ICUR) of CAD 31 243 and CAD 29 014 per QALY gained versus the next best alternative, i.e., orlistat, and SoC, respectively. Semaglutide 2.4 mg extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg and remained cost-effective both under a public and private payer perspective. Results were robust to sensitivity analyses varying post-treatment catch-up rates, longer treatment durations and using real-world cohort characteristics. Semaglutide 2.4 mg was the preferred intervention, with a likelihood of 70% at a WTP threshold of CAD 50 000 per QALY gained. However, when the modeled benefits of weight-loss on cancer, mortality, cardiovascular disease (CVD) or osteoarthritis surgeries were removed simultaneously, orlistat emerged as the best value for money compared with SoC, with an ICUR of CAD 35 723 per QALY gained. Conclusion: Semaglutide 2.4 mg was the most cost-effective treatment alternative compared with D&E or orlistat alone, and extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg. Results were sensitive to the inclusion of the combined benefits of mortality, cancer, CVD, and knee osteoarthritis.
- Open Access
- 21 December 2023
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 48 (3) , 155-162.e8
Prevalence of Adult Type 2 Diabetes Mellitus and Related Complications in Alberta, Canada: A Retrospective, Observational Study Using Administrative Data
- 21 December 2023
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 48 (3) , 155-162.e8
Open AccessPrevalence of Adult Type 2 Diabetes Mellitus and Related Complications in Alberta, Canada: A Retrospective, Observational Study Using Administrative Data
- Open Access
- 4 March 2022
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (3) , 251-268
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
The recent approval in the USA (Food and Drug Administration), Canada (Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU (European Medicines Agency) of once-weekly in...
- 4 March 2022
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (3) , 251-268
Open AccessPharmacological profile of once-weekly injectable semaglutide for chronic weight management
The recent approval in the USA (Food and Drug Administration), Canada (Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU (European Medicines Agency) of once-weekly in...
- Top Cited Papers
- 1 December 2021
- Published by Elsevier in The Lancet
- Vol. 398 (10317) , 2160-2172
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
- 1 December 2021
- Published by Elsevier in The Lancet
- Vol. 398 (10317) , 2160-2172
Top Cited PapersOnce-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
- 1 December 2015
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 39, S134-S141
Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes
- 1 December 2015
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 39, S134-S141
Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes
- 1 December 2015
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 39, S148-S154
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes
- 1 December 2015
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 39, S148-S154
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes
- 1 April 2015
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 39 (2) , 89-90
Recommendations for Obesity Management and Prevention Have Come a Long Way
- 1 April 2015
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 39 (2) , 89-90
Recommendations for Obesity Management and Prevention Have Come a Long Way
- Open Access
- 23 September 2014
- Published by Springer Nature in Systematic Reviews
- Vol. 3 (1) , 108
Do sugar-sweetened beverages cause adverse health outcomes in adults? A systematic review protocol
Chronic diseases, such as cardiovascular disease and type 2 diabetes, impose significant burden to public health. Most chronic diseases are associated with underlying preventable risk factors, such as elevated blood pressure, blood glucose, and lipids, physical inactivity, excessive sedentary behaviours, overweight and obesity, and tobacco usage. Sugar-sweetened beverages are known to be significant sources of additional caloric intake, and given recent attention to their contribution in the development of chronic diseases, a systematic review is warranted. We will assess whether the consumption of sugar-sweetened beverages in adults is associated with adverse health outcomes and what the potential moderating factors are. Of interest are studies addressing sugar-sweetened beverage consumption, taking a broad perspective. Both direct consumption studies as well as those evaluating interventions that influence consumption (e.g. school policy, educational) will be relevant. Non-specific or multi-faceted behavioural, educational, or policy interventions may also be included subject to the level of evidence that exists for the other interventions/exposures. Comparisons of interest and endpoints of interest are pre-specified. We will include randomized controlled trials, controlled clinical trials, interrupted time series studies, controlled before-after studies, prospective and retrospective comparative cohort studies, case-control studies, and nested case-control designs. The MEDLINE®, Embase, The Cochrane Library, CINAHL, ERIC, and PsycINFO® databases and grey literature sources will be searched. The processes for selecting studies, abstracting data, and resolving conflicts are described. We will assess risk of bias using design-specific tools. To determine sets of confounding variables that should be adjusted for, we have developed causal directed acyclic graphs and will use those to inform our risk of bias assessments. Meta-analysis will be conducted where appropriate; parameters for exploring statistical heterogeneity and effect modifiers are pre-specified. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used for determining the quality of evidence for outcomes. PROSPERO CRD42014009638
- 23 September 2014
- Published by Springer Nature in Systematic Reviews
- Vol. 3 (1) , 108
Open AccessDo sugar-sweetened beverages cause adverse health outcomes in adults? A systematic review protocol
Chronic diseases, such as cardiovascular disease and type 2 diabetes, impose significant burden to public health. Most chronic diseases are associated with underlying preventable risk factors, such as elevated blood pressure, blood glucose, and lipids, physical inactivity, excessive sedentary behaviours, overweight and obesity, and tobacco usage. Sugar-sweetened beverages are known to be significant sources of additional caloric intake, and given recent attention to their contribution in the development of chronic diseases, a systematic review is warranted. We will assess whether the consumption of sugar-sweetened beverages in adults is associated with adverse health outcomes and what the potential moderating factors are. Of interest are studies addressing sugar-sweetened beverage consumption, taking a broad perspective. Both direct consumption studies as well as those evaluating interventions that influence consumption (e.g. school policy, educational) will be relevant. Non-specific or multi-faceted behavioural, educational, or policy interventions may also be included subject to the level of evidence that exists for the other interventions/exposures. Comparisons of interest and endpoints of interest are pre-specified. We will include randomized controlled trials, controlled clinical trials, interrupted time series studies, controlled before-after studies, prospective and retrospective comparative cohort studies, case-control studies, and nested case-control designs. The MEDLINE®, Embase, The Cochrane Library, CINAHL, ERIC, and PsycINFO® databases and grey literature sources will be searched. The processes for selecting studies, abstracting data, and resolving conflicts are described. We will assess risk of bias using design-specific tools. To determine sets of confounding variables that should be adjusted for, we have developed causal directed acyclic graphs and will use those to inform our risk of bias assessments. Meta-analysis will be conducted where appropriate; parameters for exploring statistical heterogeneity and effect modifiers are pre-specified. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used for determining the quality of evidence for outcomes. PROSPERO CRD42014009638